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Introduction. Vaccines and antiviral drugs are the most widely 
used methods of preventing or treating Influenza virus infection. 
The role of sea buckthorn (SBT) bud dry extract as a natural anti-
viral drug against Influenza was investigated.
Methods. Influenza virus was cultured in the MDCK cell line, 
with or without SBT bud extract, and virus growth was assessed 
by HA and TCID50 virus titration in terms of cytopathic effect on 
cells. Several concentrations of extract were tested, the virus titer 
being measured on day 4 after infection.
Results. After infection, the virus titer in the control sample was 
calculated to be 2.5 TCID50/ml; treatment with SBT bud extract 
reduced the virus titer to 2.0 TCID50/ml at 50 µg/ml, while the 
HA titer was reduced from 1431 (control) to 178. Concentrations 
lower than 50µg/ml displayed an inhibitory effect in the HA assay, 
but not in the TCID50 virus titration; however, observation of 
the viral cultures confirmed a slowdown of viral growth at all 
concentrations.
Discussion. Natural dietary supplements and phytotherapy are 
a growing market and offer new opportunities for the treatment 
of several diseases and disorders. These preliminary experiments 
are the first to show that SBT bud extract is able to reduce the 
growth of the Influenza A H1N1 virus in vitro at a concentration 
of 50 µg/ml. This discovery opens up the possibility of using SBT 
bud extract as a valid weapon against Influenza and, in addition, 
as the starting-point for the discovery of new drugs.
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Summary
Introduction
Influenza is caused by RNA viruses belonging to the 
family of Orthomyxoviridae. Three types of influenza 
viruses can be distinguished. Among these, influenza A 
(IAV) viruses mainly infect birds and mammals, where-
as influenza B viruses almost only infect humans. In-
fluenza A virus displays constant evolutionary changes, 
defined as “antigenic drift” [1] and “antigenic shift” [2], 
enabling new mutant strains to emerge and spread. Influ-
enza viruses constitute a public health problem, as they 
can give rise to both epidemics and pandemics, causing 
high rates of morbidity and mortality [1]. Influenza vi-
ruses are considered the leading cause of respiratory ill-
ness in humans and are responsible for annual seasonal 
outbreaks that have a serious economic impact [3]. The 
average global burden of influenza may be in the order 
of 1 billion cases of flu, 3-5 million cases of severe ill-
ness that need hospitalization and 250,000-500,000 
deaths yearly [4]. The most effective means of fighting 
influenza is primary prevention through vaccination [5], 
which can prevent the disease after exposure or reduce 
the severity of symptoms. Antiviral drugs can also be 
used [6]. Indeed, in subjects who are not completely pro-
tected by vaccination strategies, an important role has 
been played by antiviral treatments [7].
Currently, two main classes of antiviral drugs are avail-
able; these are based on the ability to block viral M2 
ion channels [8] and viral neuraminidase [9]. However, 
both classes of drugs have been associated with limited 
efficacy, adverse side effects [1] and the spread of drug 
resistance in circulating influenza viruses [10, 11]; this 
last problem has been associated with an uncontrolled 
administration of the drugs to humans and, sometimes, 
to farm animals [12]. Other classes of drugs can be used 
against influenza virus, some of these include: inhibitors 
of hemagglutinin, endosomes, lysosomes, proteases, 
polymerases, nucleoprotein (NP), nonstructural-1 (NS1) 
glycoprotein, RNA synthesis and caspase; however their 
efficacy in blocking Influenza virus and avoiding the 
development of antiviral resistances should be further 
investigated  [13]. It is therefore necessary to develop 
new anti-influenza treatments that are able to inhibit the 
replication or cellular processes of viruses [1, 7].
Some studies have indicated that certain plant extracts 
are able to mimic the anti-neuraminidase effect of anti-
viral drugs. One of these plants is sea buckthorn (SBT) 
(Hippophae rhamnoides): commonly known as sea 
buckthorn, it belongs to the family Elaeagnaceae  [14] 
and it is a shrubby to bushy plant that grows also at a 
high altitude and is widely distributed in Eurasia. In In-
dia this plant grows predominantly in several high-alti-
tude areas such as Sikkim, Himachal Pradesh, Kashmir, 
Jammu, and Uttar Pradesh but Hippophae is cultivated 
worldwide for its medicinal properties [15].
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All parts of SBT contain large amounts of several active 
compounds [16] and these include: vitamins (folic acid, 
vitamin C, vitamin A, vitamin E, vitamin K, riboflavin), 
carotenoids (lycopene α, β, δ-carotene), phytosterols 
(amyrins, ergosterol, stigmasterol, lansterol), organic 
acids (malic and oxalic acids), polyunsaturated fatty ac-
ids and essential amino acids [17].
Several medicinal and therapeutic applications utilize 
the extracts obtained from the leaves of this plant, which 
display immunomodulatory  [18] and anti-inflammato-
ry [19] properties, as demonstrated by Padwad and col-
leagues  [16]. Furthermore, SBT leaves also exert anti-
viral, anti-bacterial and anti-tumor effects [20, 21]. Pre-
liminary results have also shown that SBT seed extracts 
have anti-bacterial activity (for example against Listeria 
monocytogenes and Yersinia enterocolitica)  [22,  23] 
and anti-viral activities, as reported by the group of Jain 
against Dengue virus [24].
SBT bud extracts are present in commercial dietary sup-
plements, such as preparations of nutrient and vitamin 
products [25, 26], and are formulated into Influpirinvi-
ral® (PoolPharma). However, no data are currently avail-
able on the putative antiviral activity of bud extracts 
when taken in the form of dietary supplements.
The aim of the present study was to evaluate the thera-
peutic anti-viral potential of SBT bud extracts on Influ-
enza A/H1N1 virus infection in Madin Darby Canine 
Kidney cells (MDCK). In 2009, this viral strain was re-
sponsible for an Influenza pandemic that spread rapidly 
around the world [27]. Moreover, it currently circulates 
in the population, causing seasonal outbreaks, and its 
antigens are included in the available seasonal influenza 
vaccines [28].
Methods
Cells and Cell Cultures
Madin Darby Canine Kidney (MDCK) cells were pur-
chased from Sigma-Aldrich (ECACC, Public Health 
England, Porton Down, United Kingdom) and cultured 
in Minimum Essential Medium Eagle (EMEM medium) 
supplemented with 2mM Glutamine, 10% Fetal Bovine 
Serum (FBS) EU Approved (Euroclone, Pero, Italy) and 
100Ul/ml of penicillin-streptomycin. Sub-confluent cul-
tures (70%-80%) were grown at 37°C in a humidified 
atmosphere containing 5% CO2, and subcultures were 
performed every 3-4 days [29]. Except where indicated 
otherwise, all the above reagents were from Lonza (Ver-
viers, Belgium).
SBT bud dry extract 
SBT bud dry extract from PoolPharma S.r.l. (San Gi-
uliano Milanese, Italy) was weighed on a precision scale 
and dissolved in sterile Dulbecco’s Phosphate-Buffered 
Saline (DPBS) at a final concentration of 1 mg/ml; the 
pH of the solution was measured (6.96). The dissolved 
extract was then sterile-filtered through a 0.22 µm filter.
Influenza A/California/7/2009 (H1N1) virus
Influenza A/California/7/2009 (H1N1) virus was ob-
tained from the National Institute for Biological Stan-
dards and Control (NIBSC) (Potters Bar, Hertfordshire, 
United Kingdom) and used according to the instructions 
provided by the supplier. The virus was propagated in 
MDCK cells  [30], harvested and stored at -80°C. The 
propagated virus had a tissue culture infectious dose 
(TCID50) titer of 103.5.
Viral growth
Influenza A/California/7/2009 (H1N1) virus was propa-
gated in MDCK cells cultured in UltraMDCK serum-
free-medium (SFM) supplemented with 0.5 μg/ml of 
trypsin from bovine pancreas (TPCK) (Sigma-Aldrich, 
Saint Louis, MO, USA) and 100 UI/ml of penicillin-
streptomycin. MDCK cells were seeded in a T25 cm2 
tissue culture flask at a density of 1 x 106 cells/ml. Af-
ter 24 hours (h), the cell medium was discarded and the 
cells were washed twice with sterile DPBS. After the 
DPBS had been discarded from the flask, the cells were 
treated with 500 µl of virus inoculum (5 ml of solution 
contained 50 µl of virus at 103.5 TCID50/ml (1:100 dilu-
tion) and 2.5 µl of TPCK, and incubated for 1 h at 37°C 
in 5% CO2. After 1 h, the inoculum was removed, the 
cells were washed with DPBS, and fresh UltraMDCK 
SFM, supplemented as previously described, was add-
ed. The cells were incubated at 37°C in 5% CO2 and the 
cytopathic effect was monitored every day until post-
infection day 4. The culture medium was collected and 
analyzed for TCID50 and hemagglutination titer on the 
4th day after infection.
Effect of SBT bud dry extract on MDCK 
cells
MDCK cells were seeded at a density of 6.5 x 105 cells/
ml in 6-well plates in complete EMEM medium and 
were incubated for 24 h at 37°C in 5% CO2. SBT at dif-
ferent concentrations (1 μg/ml, 5 μg/ml, 10 μg/ml, 30 μg/
ml, 50 μg/ml, 75 μg/ml and 100 μg/ml) was then added 
to the medium in the wells. The cells were checked at 24 
h, 48 h and 72 h by means of a light optical microscope 
to evaluate whether the extract had a cytotoxic effect on 
them. The experiment was repeated to confirm the pre-
liminary results.
Effect of SBT on viral growth
The viral growth procedure was repeated in the condi-
tions reported above. After infection, the inoculum was 
removed and the medium was replaced with fresh Ultra-
MDCK SFM (supplemented with 100 UI/ml of penicil-
lin-streptomycin and 0.5 g/ml of TPCK) containing dif-
ferent concentrations of SBT: 2.5 μg/ml, 5 μg/ml, 7.5 μg/
ml, 10 μg/ml, 30 μg/ml, 50 μg/ml, 75 μg/ml and 100 μg/
ml. The infection grade was observed daily for cytopath-
ic effect, and the culture medium was harvested on day 4 
to be analyzed for virus content in terms of TCID50 and 
hemagglutination titer. In parallel, two control flasks 
were run: the first flask represented the cell control and 
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the culture medium was added with DPBS; the second 
flask represented the virus growth control and it was 
treated only with the live virus.
Virus titration by hemagglutination test
The ability of the influenza virus to agglutinate red 
blood cells from certain mammalian or avian species can 
be exploited to check for the presence and hemaggluti-
nating activity of the virus in biological substrates (e.g. 
serum samples) [31, 32]. To evaluate the hemagglutinat-
ing capability of the virus in previously infected cell cul-
tures, the hemagglutination test was used: 100 µl of cul-
ture medium from the flask of interest was transferred 
to the 1st well of 12 of a 96-well V bottom plate then 50 
μl of saline solution (0.9% NaCl) (Sigma-Aldrich, Saint 
Louis, MO, USA) was added from well 2 up to well 12; 
2-fold serial dilutions of the culture medium (contained 
in the 1st well) in the saline solution (wells 2-12) were 
performed from the 1st well up to the 12th well.
Then, 50 µl of turkey red blood cell (RBC) suspension 
(0.5% in saline solution) (Emozoo Snc, Casole d’Elsa, 
Italy) was added to each well and the plate was incu-
bated for 45 minutes at room temperature (RT). After 
incubation, the plate was tilted to allow non-hemagglu-
tinated RBCs to drip from the bottom of the wells and 
the result was read; the reciprocal of the highest dilution 
of the culture medium that was still able to cause ag-
glutination indicated the titer of the virus in the culture 
medium. The experiment was repeated, this time with a 
1:10 starting dilution of the culture media, and the virus 
titer was calculated in terms of hemagglutinating units 
(HAU) in 1 ml by applying the following formula: HAU 
in 1 ml=20x10[LOG(Dilution1)+LOG(Dilution2)]/2 .
Virus titration by TCID50
The “TCID50” titer is the viral dose that gives rise to a 
cytopathic effect in 50% of cells in the inoculated cul-
ture. The virus titer was determined by means of the 
TCID50 assay, using the Spearman/Karber method [33] 
on treated MDCK cells, as reported by Lugovtsev [34]. 
Twelve plastic tubes (1.5 ml) were prepared and loaded 
with 900 μl of cell medium (EMEM), except for the 
11th tube; 100 µl of supernatants from cultures was then 
transferred into the first tube and serial 10-fold dilutions 
were performed from tube 1 to up to tube 10. The con-
tents of the tubes were transferred into a 96-well cell 
culture plate: the content of the 1st tube was transferred 
into the 1st column of the plate, the content of the 2nd tube 
was transferred into the 2nd column, and so on up to the 
10th tube. The 11th column was left empty. At the end 
of the dilution steps, 100 μl of cell suspension (in com-
plete EMEM medium, with 0.5% FBS and 0.5 μg/ml of 
TPCK, at a cell density of 5 x 105 cells/ml) was added 
to each well. The 12th column, containing only cell me-
dium and cell suspension, was used as a cell control. 
The plates were incubated for 5 days and the TCID50 
titer was evaluated by checking the cytopathic effect 
in the cell mono-layer by means of a light microscope. 
The results were calculated by applying the Spearman/
Karber formula [33]: TCID50/100µl= X0-d/2+d(ΣXi/n), 
where X0 is the positive logarithm of the highest dilu-
tion at which all wells are positive for cytopathic effect, 
d represents the dose distance in log, n is the number 
of repeats per dilution and ΣXi is the sum of all posi-
tive wells, starting from X0. In the case of 10-fold dilu-
tion, d=log1010=1 and the formula can be simplified to 
TCID50/100μl= X0-1/2+(ΣXi/n). To express the results 
as TCID50/ml, one log was added.
Results
Evaluation of the cytotoxic effect of SBT 
on MDCK Cells 
The possible cytotoxic effect of SBT on MDCK cells 
previously infected with Influenza A H1N1 virus was 
evaluated by means of direct observation of cells under a 
light optical microscope. SBT treatment of MDCK cells 
showed no cytotoxic effect up to a concentration of 50 
µg/ml. At 75 μg/ml and 100 μg/ml, SBT had a cytotoxic 
effect on the cells: at 75 μg/ml, the cell monolayer had 
a discontinuous appearance and floating cells were pre-
sent in the culture medium; this effect was more evident 
at a concentration of 100 μg/ml (Tab. I). 
SBT effect on viral growth results
Hemagglutination titer results
The ability of SBT bud extract to reduce Influenza 
H1N1 viral growth was evaluated on post-infection day 
4. MDCK cell culture supernatants were harvested from 
the culture plates and assayed for hemagglutination ti-
ter. Concentrations of SBT ranging from 2.5 μg/ml to 
50 μg/ml markedly reduced the hemagglutination titer 
from 28621.6 HAU/ml (the value obtained from the 
viral growth control sample) (Fig. 1). The two highest 
concentrations of SBT used (75 μg/ml and 100 μg/ml) 
completely inhibited viral growth. However, they dis-
Tab. I. evaluation of the cytotoxic effect of SBT on mdCK Cells. This 
table shows the effect of different concentrations of SBT on mdCK 
cell cultures after 72 h of incubation. The concentrations of SBT test-
ed were: 1 μg/ml, 5 μg/ml, 10 μg/ml, 30 μg/ml, 50 μg/ml, 75 μg/ml 
and 100μg/ml. No toxic effect was observed up to a concentration 
of 75 μg/ml. At 75 μg/ml and 100 μg/ml of SBT, the cells in the wells 
showed signs of toxicity: discontinuous cell layer and floating cells 
in the medium.
SBT concentration effect
Cell control No effect
1 µg/ml No effect
5 µg/ml No effect
10 µg/ml No effect
30 µg/ml No effect
50 µg/ml No effect
75 µg/ml discontinuous cell layer, floating cells
100 µg/ml discontinuous cell layer, floating cells
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played a toxic effect on the cells; the results obtained at 
these high concentrations may therefore be affected cell 
toxicity, as was observed after staining the cell cultures 
with Trypan blue.
TCID50 virus titration results
Cell culture supernatants were harvested on day 4 after 
infection and treatment and assayed for TCID50 virus 
titer to assess the number of infectious (live) viral par-
ticles released from the infected cells in the culture me-
dium. The cytopathic effect was evaluated on day 5. The 
treatment of viral cultures with SBT at a concentration 
of 50 µg/ml markedly reduced the viral titer in terms of 
TCID50 (Fig. 2). At 75 µg/ml and 100 µg/ml, SBT was 
able to inhibit viral growth completely; however, this 
value could be affected by the toxicity that SBT showed 
on cells at such high concentrations. Direct observation 
of the viral cultures confirmed the results obtained from 
TCID50 and hemagglutination titration. The concentra-
tion of SBT that proved to have the greatest impact on 
viral growth while exerting little negative effect on cells 
was 50 µg/ml. Figure 3 reports a series of representative 
pictures showing the effect of SBT at 0, 10, 30, 50, 75 
and 100 µg/ml on day 4 on MDCK cells infected with 
Influenza A/H1N1 virus.
Discussion
In recent years, since the spread of resistant viral strain 
towards the available pharmacologic treatments and the 
occurrence of unpredictable pandemics, many investiga-
tions have been carried out on new computer-designed 
molecules or available compounds in a search for new 
Fig. 3. Cell viability of mdCK cells infected with Influenza h1N1 
upon treatment with SBT. The figure shows a series of repre-
sentative pictures from the light optical microscope (Trypan 
blue-stained; original magnification 100X) showing mdCK cell cul-
tures infected with Influenza virus h1N1 A/California/7/2009 and 
treated with different concentrations of SBT: A, virus control; B, 
10 µg/ml; C, 30 µg/ml; d, 50 µg/ml; e, 75 µg/ml; F, 100 µg/ml. 
Cells were stained with Trypan blue to observe dead cells. The 
virus control displayed a large number of dead cells (blue spots); 
10 µg/ml and 30 µg/ml of SBT induced a reduction in the number 
of dead cells, and the cellular monolayer was more compact. pic-
ture d represents the 50 µg/ml SBT concentration: no cytopathic 
effect and a limited number of dead cells. The 75 µg/ml and 100 
µg/ml SBT concentrations showed a discontinuous cell layer with 
many dead cells in the culture medium.
Fig. 2. TCId50 virus titration results. The graph shows the results 
of the TCId50 titration assay performed on supernatants from vi-
ral mdCK cultures treated with SBT. The values of the TCId50 titer 
in 1 ml are shown on the y axis; on the x axis the concentrations 
of SBT used to treat viral cultures are reported: 0 μg/ml (virus 
control), 2.5 μg/ml, 5 μg/ml, 7.5 μg/ml, 10 μg/ml, 30 μg/ml, 50 
μg/ml, 75 μg/ml and 100 μg/ml. The virus control displayed a 
titer of 102.5 TCId50; the TCId50 titer was reduced when SBT was 
used at a concentration of 50 μg/ml. At 75 μg/ml and 100 μg/ml, 
SBT inhibited viral growth totally. These results represent a mean 
of two experiments (n = 2).
Fig. 1. hemagglutination Titration results on day 4 after SBT treat-
ment. Supernatants of viral cultures treated with SBT were ana-
lyzed by means of hemagglutination assay to determine whether 
the treatment was able to reduce the spread of Influenza virus. 
The values of the hemagglutination titer in 1 ml (volume assayed) 
are shown on the y axis; the x axis reports the concentrations of 
SBT (2.5 μg/ml, 5 μg/ml, 7.5 μg/ml, 10 μg/ml, 30 μg/ml, 50 μg/ml, 
75 μg/ml and 100 μg/ml) used to treat viral cultures. No SBT was 
added to the virus control sample. The control sample displayed 
a titer of 28636; treatment with SBT dramatically decreased the 
hemagglutination titer. The most effective concentration of SBT 
was 50 μg/ml. At 75μg/ml and 100μg/ml, SBT totally inhibited 
viral growth, but in these cases the results could be affected by 
SBT toxicity. These results represent a mean of two experiments 
(n = 2).
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anti-influenza drugs. In the present study, the antiviral 
activity of SBT bud extract (contained in Influpirinvi-
ral®) against influenza H1N1 A/California/7/2009 was 
evaluated in vitro on MDCK cells infected with this 
virus. A previous study conducted by Jain and col-
leagues  [24] demonstrated that SBT leaf extract at a 
concentration of 50 μg/ml exerted an antiviral activity 
against Dengue virus. We found that SBT bud extract 
had an antiviral activity on influenza virus H1N1, espe-
cially at 50 μg/ml (the same concentration used by Jain’s 
group). Specifically, after 4 days the viral titer was eval-
uated in terms of TCID50 titer and hemagglutination ti-
ter upon treatment with SBT bud extract; both methods 
revealed that, at 50 μg/ml, the viral titer was reduced 
in comparison with the virus control. Direct observation 
of the virus cultures confirmed the antiviral activity at 
50 μg/ml, although an antiviral effect was also visible 
at lower concentrations, starting from 2.5 μg/ml. When 
SBT was used at high concentrations (75 μg/ml and 100 
μg/ml), viral growth was completely inhibited. Howev-
er, the treatment had an adverse effect on cell cultures, 
and this could have affected the results obtained at these 
concentrations. 
Conclusions
The data obtained from this preliminary study confirmed 
that SBT bud extract has an antiviral activity on influ-
enza H1N1 A/California/7/2009 in vitro, supporting its 
potential use as an anti-influenza agent. Nevertheless, 
further investigations are needed in order to generate 
more data, to evaluate the preventive role of SBT treat-
ment against Influenza infection, and to understand the 
specific mechanism of action of this extract both in vitro 
and in vivo.
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